{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:48:05Z","timestamp":1792025285110,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clbc.2026.09.009","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:29:33Z","timestamp":1789914573000},"page":"25-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Baseline Metabolic Tumor Volume on [18F]FDG PET\/CT in Metastatic Breast Cancer Treated With CDK4\/6 Inhibitors"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9526-0360","authenticated-orcid":false,"given":"Seyma","family":"Erdogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusufcan","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3244-4832","authenticated-orcid":false,"given":"Elif Reyhan","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refia","family":"Yukselturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8917-9267","authenticated-orcid":false,"given":"Efnan","family":"Alg\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berna","family":"Okudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Inan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oznur","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clbc.2026.09.009_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.clbc.2026.09.009_bib0002","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2026.09.009_bib0003","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines insights: breast cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clbc.2026.09.009_bib0004","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.2147\/CMAR.S300869","article-title":"Prognostic factors in hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: a systematic literature review","volume":"13","author":"Carter","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.clbc.2026.09.009_bib0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.15406\/ijmboa.2024.07.00184","article-title":"Tumor heterogeneity in clinical interpretation of PET\/CT imaging: evaluation of metabolic tumor volume, total lesion glycolysis, and standardized uptake value","volume":"7","author":"Colmenter","year":"2024","journal-title":"Int J Mol Biol Open Access"},{"key":"10.1016\/j.clbc.2026.09.009_bib0006","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/MNM.0000000000001227","article-title":"Prognostic value of metabolic tumor volume and total lesion glycolysis in breast cancer: a meta-analysis","volume":"41","author":"Pak","year":"2020","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.clbc.2026.09.009_bib0007","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2214\/AJR.14.13906","article-title":"Whole-body metabolic tumor volume as a prognostic factor of outcome in patients with breast cancer and distant metastasis","volume":"205","author":"Son","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.clbc.2026.09.009_bib0008","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ijrobp.2013.08.001","article-title":"Volume-based FDG PET\/CT parameters improve disease recurrence prediction in postmastectomy breast cancer patients with one to three positive axillary lymph nodes","volume":"87","author":"Nakajima","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clbc.2026.09.009_bib0009","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s13139-012-0161-9","article-title":"Prognostic significance of metabolic tumor volume measured by FDG PET\/CT in operable primary breast cancer","volume":"46","author":"Kim","year":"2012","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.clbc.2026.09.009_bib0010","first-page":"120","article-title":"Prognostic value of FDG PET\/CT-based metabolic tumor volume in metastatic triple-negative breast cancer patients","volume":"6","author":"Marinelli","year":"2016","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clbc.2026.09.009_bib0011","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-026-08056-1","article-title":"Prognostic relevance of [18F]FDG PET\/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial","author":"Urso","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.clbc.2026.09.009_bib0012","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/MNM.0000000000001500","article-title":"Impact on the long-term prognosis of FDG PET\/CT in luminal-A and luminal-B breast cancer","volume":"43","author":"Urso","year":"2021","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.clbc.2026.09.009_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1193174","article-title":"Prognostic value of [18F]-FDG PET\/CT in patients with meta-static breast cancer treated with cyclin-dependent inhibitors","volume":"13","author":"Annovazzi","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2026.09.009_bib0014","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.21873\/anticanres.15986","article-title":"Total lesion glycolysis levels as predictive indicators in patients with metastatic and rec urrent breast cancer undergoing endocrine therapy with or without CDK4\/6 inhibitor","volume":"42","author":"Ozawa","year":"2022","journal-title":"Anticancer Res"},{"issue":"9","key":"10.1016\/j.clbc.2026.09.009_bib0015","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","article-title":"Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI\/ESR, and EUSOMA)","volume":"51","author":"Vaz","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clbc.2026.09.009_bib0016","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.21037\/tcr-20-2119","article-title":"Prognostic factors for patients with metastatic breast cancer: a literature review","volume":"10","author":"Hu","year":"2021","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.clbc.2026.09.009_bib0017","first-page":"1","article-title":"Determinants of response to CDK4\/6 inhibitors in the real-world setting","volume":"7","author":"Witkiewicz","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.clbc.2026.09.009_bib0018","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.09.009_bib0019","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clbc.2026.09.009_bib0020","article-title":"The neoadjuvant approach to treatment of breast cancer: multidisciplinary management to improve outcomes","volume":"1","author":"Baskin","year":"2024","journal-title":"Surg Oncol Insight"},{"key":"10.1016\/j.clbc.2026.09.009_bib0021","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdq220","article-title":"Survival differences among women with de novo stage IV and relapsed breast cancer","volume":"21","author":"Dawood","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.09.009_bib0022","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/jcmm.17486","article-title":"In vitro radiosensitization of breast cancer with hypoxia-activated prodrugs","volume":"26","author":"Aiyappa-Maudsley","year":"2022","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.clbc.2026.09.009_bib0023","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00595-024-02893-z","article-title":"Identification of peripheral blood test parameters predicting response to palbociclib and endocrine therapy for metastatic breast cancer: a retrospective single-institution study","volume":"55","author":"Yamamoto","year":"2024","journal-title":"Surg Today"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:29:18Z","timestamp":1792024158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926001722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1526820926001722"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.09.009","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Value of Baseline Metabolic Tumor Volume on [18F]FDG PET\/CT in Metastatic Breast Cancer Treated With CDK4\/6 Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}